Bioanalytical Systems, Inc. (NASDAQ:BASI) Director Wendy Perrow Acquires 10,000 Shares

Share on StockTwits

Bioanalytical Systems, Inc. (NASDAQ:BASI) Director Wendy Perrow bought 10,000 shares of Bioanalytical Systems stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $3.62 per share, for a total transaction of $36,200.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $36,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of BASI traded up $0.03 on Wednesday, hitting $3.61. 105,500 shares of the stock traded hands, compared to its average volume of 22,733. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.61 and a current ratio of 0.67. The stock’s 50 day moving average is $2.42 and its two-hundred day moving average is $2.07. Bioanalytical Systems, Inc. has a 1 year low of $1.18 and a 1 year high of $3.74.

Bioanalytical Systems (NASDAQ:BASI) last announced its earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $10.86 million for the quarter. Bioanalytical Systems had a negative return on equity of 7.90% and a negative net margin of 3.38%.

Separately, ValuEngine downgraded Bioanalytical Systems from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th.

An institutional investor recently raised its position in Bioanalytical Systems stock. Renaissance Technologies LLC lifted its holdings in shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) by 7.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 253,001 shares of the company’s stock after purchasing an additional 18,120 shares during the quarter. Renaissance Technologies LLC owned about 2.46% of Bioanalytical Systems worth $506,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.04% of the company’s stock.

About Bioanalytical Systems

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

Featured Article: What is a Fibonacci Channel?

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with's FREE daily email newsletter.